While we observed a positive treatment effect of BC007, a Phase II clinical trial by Berlin Cures GmbH (BLOC) did not show a superior effect compared to placebo, as announced in a press release <a href="
https://www.medrxiv.org/content/10.1101/2024.12.13.24318856v1.full#ref-24">24</a>. Detailed participant characteristics and outcomes from BLOC have not been shared. Both trials included PCS patients with detectable GPCR-fAAbs, but there were key differences: BLOC used a randomised design, while reCOVer was a crossover study; inclusion criteria for fatigue severity differed (reCOVer: Bell Score≤60; BLOC: FACIT-FS Score<35); the duration of PCS symptoms varied (reCOVer: at least three months before enrolment; BLOC: „acute phase of COVID-19 ended at least 3 months prior to dosing“). Additionally, the reCOVer trial excluded patients with ‘organ damage.’ These differences may explain the discrepant results, though an in-depth analysis of the BLOC trial is needed to confirm this. No data on treatment success or detailed analysis have been provided from BLOC.